Navigation For Mobile

Author Archives: Saharsh Davuluri

Looking for an API Supplier? 5 Things to Consider (Updated)

Seven years ago – in March of 2013 – we published a blog post on 5 Things to Consider When Looking for an API Supplier. Because seven human years equals…

Posted in API synthesis, APIs, Chemistry, CMC, Contract Manufacturing, drugs, FDA, Neuland Labs, process chemistry, Process Engineering, Project Management, Quality, R&D, regulatory, supply chain, synthesis | Tagged , , | Comments Off on Looking for an API Supplier? 5 Things to Consider (Updated)

Pharma Drug Innovation in 2020: From Novel Drugs to Drugs for Novel Coronavirus

Have other areas in drug discovery suffered because of COVID-19? It’s probably not too early to say that COVID-19 has changed pharmaceutical drug discovery considerably. And why wouldn’t it have,…

Posted in Chemistry, drug discovery, drugs, FDA, Neuland Labs, R&D, regulatory | Tagged , , | Comments Off on Pharma Drug Innovation in 2020: From Novel Drugs to Drugs for Novel Coronavirus

While the U.S. Worries Over Supply Chains, India Seeks Solutions: Atmanirbhar Bharat

Starting in March, PPE – personal protective equipment, including gloves, gowns and face masks – became as valuable as gold…and nearly as rare. During a media briefing on March 27,…

Posted in COVID19, India, supply chain | Tagged , , , , , , | Comments Off on While the U.S. Worries Over Supply Chains, India Seeks Solutions: Atmanirbhar Bharat

Pharma Manufacturing Operations in the Time of COVID-19

There has been a flood of articles recently on how companies have adapted to our new reality in a coronavirus-affected world. As an essential services manufacturer and lab, Neuland has…

Posted in COVID19, EHS, Neuland Labs | Tagged , , , | Comments Off on Pharma Manufacturing Operations in the Time of COVID-19

Beyond COVID-19: What Else in Happening in Pharma?

Around the world, pharma and biopharma – along with all of the supporting industries, from suppliers and research organizations to outsourced providers – have been exclusively focused on COVID-19. With…

Posted in APIs, drug delivery, drugs, peptide, peptides | Tagged , , , | Comments Off on Beyond COVID-19: What Else in Happening in Pharma?

China Launches New Marketing Authorization Holder (MAH) System

In December 2019, China issued a revision to their Drug Administration Law. It was the most wide-ranging modification of their laws since 2001. It marked a fundamental shift away from…

Posted in API synthesis, APIs, drug discovery, drugs, regulatory | Comments Off on China Launches New Marketing Authorization Holder (MAH) System

Video: Pharmaceutical Analytical Capabilities & Drug Quality

Drug quality and strong analytical capabilities go hand-in-hand. It is virtually impossible to achieve the former without the latter at all stages of a drug’s development and production.

Posted in API synthesis, APIs, Chemistry, chromatography, drugs, QA/QC, Quality | Tagged , , , | Comments Off on Video: Pharmaceutical Analytical Capabilities & Drug Quality

Process Validation: Maintaining Quality Consistency

The basic principle of pharmaceutical quality assurance is that a drug should be safe and effective for its intended use – and process validation plays a pivotal role in ensuring…

Posted in APIs, Chemistry, process chemistry, Process Engineering, QA/QC | Tagged , , , | Comments Off on Process Validation: Maintaining Quality Consistency

Coronavirus & Drug Supply Chains: The Pharma Industry Searches for Answers

Coronavirus has impacted drug supply chains. At first blush, people will likely read that sentence to mean drugs aren’t arriving at their intended destination. That precursor chemicals, intermediaries, APIs, or…

Posted in APIs, Contract Manufacturing, drugs, Effluent, EHS, green chemistry, outsourcing, supply chain | Tagged , , | Comments Off on Coronavirus & Drug Supply Chains: The Pharma Industry Searches for Answers

On-Site Pharma Audits During the Coronavirus (COVID-19) Crisis

The outbreak of COVID-19 has significantly impacted physical visits to drug manufacturing facilities. This raises a number of challenges, since many regulations — especially those relating to inspections — weren’t written with…

Posted in APIs, CMC, drugs, FDA, Quality, regulatory | Tagged , , , , | Comments Off on On-Site Pharma Audits During the Coronavirus (COVID-19) Crisis